Ymmunobio AG, a preclinical stage biotech company specializing in the development of CEACAM (carcinoembryonic antigen-related cell adhesion molecules) antibodies as anti-cancer treatments, has been selected by BIO-Europe 2022 to present at the Start-up Spotlight session on October 25, 2022 in Leipzig, Germany.
“We’re looking forward to sharing our findings with this very innovative BIO-Europe 2022 group,” said Dr. Katrin Rupalla, CEO, Ymmunobio AG. Dr. Rupalla will present Ymmunobio’s company focus on enabling new cancer treatments by increasing immune cell communication.
The Startup Spotlight is a pitch competition featuring the most innovative startup biotech companies. This live pitch competition gives a group of hand-selected startups the opportunity to pitch in front of the BIO-Europe audience. Selected companies will present a four-minute pitch and participate in a live feedback session with a jury of leading investors, pharma dealmakers, and biotech business key opinion leaders who will evaluate the pitches and select the winner onsite.
BIO-Europe 2022 takes place October 24-26 and attracts a wide range of business leaders, such as senior executives of leading biotech companies, business development teams from large and midsize pharmaceutical companies, investors, and other industry experts. The competition will begin in Multi-purpose Room 3 at 3:30 pm at the Leipzig Messe in Leipzig, Germany, October 25, 2022.
Priority medicines (PRIME) is a scheme run by the European Medicines Agency (EMA) to enhance support for the development of medicines that target an unmet medical need. The scheme is based on enhanced interaction and early dialogue with developers of promising medicines, to optimize development plans and speed up evaluation so these medicines can reach patients earlier EMA CHMP acknowledges that n
LubioScience GmbH, Switzerland’s leading Life Sciences platform, expands its product portfolio with the addition of fresh human blood products and biospecimens provided by Research Donors from the UK.
Preliminary data from 472 nine-month-old infants confirm favorable safety and tolerability profile and demonstrate significant immunogenicity for the four most common pathogen serotypes Results support further development with LimmaTech expecting to initiate the next clinical trial in 2024 Topline results from the completed Phase I/II will be reported in the first half of 2024
InterAx Biotech AG, a product development company pioneering computational pharmacology for drug discovery, announces that the company's most advanced artificial intelligence platform has uncovered novel cellular signaling modes of action which enable InterAx to design efficacious orally available drugs for diabetes, obesity, and immuno oncology. Particularly promising results are coming from the
Its proprietary innovative polymer technology reduces bacterial bioburden without triggering antimicrobial resistance, one of the top global public health threats The Advanced Wound Dressing (AWD) market is valued at 4.5 billion USD and is witnessing increasing demand and technological advancements The company is looking to expand development and commercial collaborations with industry leaders
Vandria is advancing a portfolio of mitophagy inducers to address age-related chronic diseases of the CNS, muscle, lung and liver Innosuisse grant totalling CHF 2.5M (€ 2.7M) to support early clinical development plan for lead CNS mitophagy drug candidate VNA-318 that has the potential to treat cognitive impairment, dementia, Alzheimer’s and Parkinson’s Disease Eurostars grant totalling €1